328 research outputs found
Lapatinib nel tumore mammario metastatico HER2-positivo. suggerimenti dall’ Esmo 2014
L’Human Epidermal Growth Factor Receptor 2 (HER2) è un importante recettore per fattori di crescita appartenente alla famiglia dei recettori HER che regola la proliferazione, la differenziazione e la sopravvivenza cellulare
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs?
We read with interest the paper by Pavone and colleagues [1]
describing the rapid reduction of fasting glucose (FG) levels in diabetic
hepatitis C virus (HCV)-positive patients receiving directacting
antiviral agents (DAAs).
We aimed to assess if a similar decreasing trend of FG levels
occurred in our study population and if it was maintained after the
end of treatment (EOT). Therefore, we retrospectively evaluated
449 patients treated with DAAs at our centre (64 HIV/HCV coinfected)
Association between proton-pump inhibitors (PPI) and metronomic capecitabine (MCAP) as salvage treatment for patients with advanced gastro-intestinal tumoursa. A randomized phase II study
Background: Several researches have shown that acidification of tumor microenvironment is the basis for tumor invasiveness, ability to metastasize
S382 Abstracts and cytotoxic agents resistance; therefore proton pump inhibitors (PPI) could significantly increase the chemosensitivity. In our retrospective work we have investigated the role of capecitabine (mCAP) at metronomic dosage of 1500 mg/die as salvage chemotherapy in patients with metastatic colorectal cancer, showing a moderately activity and well tolerability. In this prospective study we evaluated safety and activity of mCAP in the advanced gastro-intestinal patients and the putative chemosensitizing activity of a specific PPI (Rabeprazole) in association to this therap
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety
Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA)
Combination therapy of high-dose rabeprazole plus metronomic capecitabine in advanced gastrointestinal cancer: a randomized phase II trial
Abstract: Background: In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose
tomodulate tumormicroenvironment acidification thus restoring chemotherapeutic sensitivity. This is the
first trial to study activity and safety of repurposing high dose rabeprazole combined with metronomic
capecitabine (mCAP). Methods: A phase II study in which patients with gastrointestinal cancer,
refractory to standard treatments, who had a life expectancy >3 months, were blind randomized
1:1 to mCAP, 1500 mg/daily, continuously with or without rabeprazole 1.5 mg/kg bid, three days
a week. The primary endpoint was 3-months progression-free survival (PFS). The secondary
endpoints were clinical benefit (CB) and overall survival (OS). Safety and plasma concentrations
of capecitabine and its metabolites (50-DFUR and 5-FU) were also evaluated. Results: Sixty-seven
(median age 69 years; 63% male; 84% colorectal cancer, 76% ECOG-PS 1; 84% pretreated with
two or more lines of chemotherapy) out of 90 patients screened for eligibility, were randomized
to receive mCAP+rabeprazole (n = 32) vs. mCAP (n = 35). All patients were evaluable for
response. No significant dierence between mCAP+rabeprazole vs. mCAP, in terms of 3-months PFS rate (HR = 1.43, 95%CI 0.53–3.85; p = 0.477), median PFS (HR = 1.22, 95%CI 0.75–2.00, p = 0.420),
CB (RR = 0.85, 95%CI 0.29–2.44; p = 0.786) and median OS (HR = 0.89, 95%CI 0.54–1.48; p = 0.664)
was observed. However, a 3-year OS rate of 10% and 12% was reported in the mCAP-rabeprazole
and mCAP groups, respectively. Overall, no grade 3 or 4 toxicity occurred but grade 1 or 2 adverse
event of any type were more frequently in the mCAP+rabeprazole group than in the mCAP (OR 2.83,
95%CI 1.03–7.79; p = 0.043). Finally, there was not statistically significant dierence in the plasma
concentration of capecitabine and its metabolites between the two groups. Conclusions: Although
the adjunct of high dose rabeprazole to mCAP was not shown to aect mCAP activity, as PPI are
being investigated worldwide as drugs to be repositioned in cancer treatment and also considering
the limited sample size as well as the favorable safety profile of the combination in the present study,
further clinical investigations are desirable
Correlation between visual field index and quality of life in glaucoma patients: a new tool to screen quality of life perception?
PurposeTo evaluate the correlation between the visual field index (VFI) and vision-related quality of life (QoL) considering several confounding variables that may have a positive or negative effect.MethodsWe conducted a cross-sectional, mono-centric study on glaucoma patients. Quality of life was examined with the NEI-VFQ 25 and the Glaucoma Symptom Scale (GSS). The visual field was examined with the Humphrey Field Analyzer. The variables considered were age, gender, comorbidities, years (at diagnosis and duration of the illness), treatment and related active principles, intraocular pressure, and visual acuity. The analysis was performed on both the better and the worse eye. The linear regression univariate analysis and the multivariate analyses were performed.ResultsIn total, 193 patients enrolled in the study. The mean age was 70.8 ± 10.4 years. The mean follow-up period since diagnosis 11.4 ± 9.2 years. Approximately 50% of the patients suffered from primary open angle glaucoma (POAG) and 45% were on monotherapy. The mean VFI was 81.3 ± 26. Regarding QoL, the NEI-VFQ total mean was 80.4 ± 17.8 and the GSS total score was 77.2 ± 21. Regarding NEI-VFQ 25, the single linear regression analysis found the following relations: age at time of visit (r = −0.30, p = 0.016), years of illness (r = −0.32, p = 0.020), the minimum and maximal visual acuity (r = 2.04 and r = 3.96, p < 0.001), the IOP min (r = 1.13, p = 0.002) and max (r = −0.52, p = 0.017), and the number of previous surgeries (r = −3.94, p < 0.001). The multivariate analysis found the following relations: gender (r = 5.13, p = 0.019), visual acuity max (r = 3.16, p < 0.001), and previous surgeries (r = −1.80, p = 0.032). Regarding GSS, the single linear regression analysis found relations with visual acuity (r = 2.37, p < 0.001), VFI (r = 0.41, p < 0.001), previous surgeries in the eye considered (r = −7.27, p < 0.001), and number of instillations (r = −3.67, p = 0.031). Data confirmed that a higher VFI has a positive impact on the score of both the NEI-VFQ 25 (r = 0.22, p = < 0.001) and the GSS questionnaire (r = 0.36, p < 0.001).ConclusionsThe study demonstrated a correlation between the VFI and QoL of patients and their visual and non-visual ocular symptoms and function both in the worst and in the better eye, even when accounting for several clinical and demographic confounding variables. Our data support that the visual field index is an important metric instrument in the follow up of patients with glaucoma
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life”
Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the PFS and OS safety in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units
- …